



1751 BOX/504

BEST AVAILABLE COPY

Attorney Docket No.: 4318.224-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bisgaard-Frantzen et al. Confirmation No: 7527

Serial No.: 09/902,188 Group Art Unit: 1751

Filed: July 10, 2001 Examiner: To be assigned

For: Amylase Variants

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

RECEIVED
OCT 03 2001
TC 1700

Box Sequence
Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:


- 1. Response to Notice to Comply with Sequence Rules
- 2. Sequence Listing
- 3. Copy of Notice to Comply with Sequence Rules
- 5. Disk Containing Sequence Listing


is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Box Sequence
Commissioner for Patents
Washington, DC 20231

on September 26, 2001.

Kelley O'Patry
(name of person mailing paper)


(signature of person mailing paper)



BEST AVAILABLE COPY
 UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
 www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/902,188	07/10/2001	Henrik Bisgard-Frantzen	4318.224-US

CONFIRMATION NO. 7527

25908
 NOVOZYMES NORTH AMERICA, INC.
 C/O NOVO NORDISK OF NORTH AMERICA, INC.
 405 LEXINGTON AVENUE, SUITE 6400
 NEW YORK, NY 10174

FORMALITIES LETTER



OC00000006360134

Date Mailed: 07/30/2001

RECEIVED

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
 CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
 DISCLOSURES**

TC 1700

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

148

Customer Service Center

Initial Patent Examination Division (703) 308-1202

BEST AVAILABLE COPY
PART 2 - COPY TO BE RETURNED WITH RESPONSE